Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma von Liniker, E, Kong, B, Menzies, A.M, Cooper, A.J, Kefford, R.F, Fogarty, G.B, Guminski, A, Carlino, M.S, Wang, T.W, Long, G.V, Hong, A

Volltext

3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma von Liniker, E, Kong, B, Menzies, A.M, Cooper, A, Ramanujam, S, Lo, S, Kefford, R.F, Fogarty, G.B, Guminski, A, Wang, T.W, Carlino, M.S, Hong, A, Long, G.V

Volltext

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma von Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J., Kefford, R.F., Carlino, M.S., Rizos, H.

Volltext

Adjuvant therapy of cutaneous melanoma: the interferon debate von KEFFORD, R. F

Volltext

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients von Lee, J.H., Saw, R.P., Thompson, J.F., Lo, S., Spillane, A.J., Shannon, K.F., Stretch, J.R., Howle, J., Menzies, A.M., Carlino, M.S., Kefford, R.F., Long, G.V., Scolyer, R.A., Rizos, H.

Volltext

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma von Anforth, R.M., Blumetti, T.C.M.P., Kefford, R.F., Sharma, R., Scolyer, R.A., Kossard, S., Long, G.V., Fernandez-Peñas, P.

Volltext

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma von Todd, J R, Scurr, L L, Becker, T M, Kefford, R F, Rizos, H

Volltext

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor von Becker, T M, Boyd, S C, Mijatov, B, Gowrishankar, K, Snoyman, S, Pupo, G M, Scolyer, R A, Mann, G J, Kefford, R F, Zhang, X D, Rizos, H

Volltext

Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules von Robert, C., Joshua, A.M., Weber, J.S., Ribas, A., Hodi, F.S., Kefford, R.F., Daud, A., Wolchok, J.D., Hwu, W-J., Gangadhar, T.C., Patnaik, A., Hersey, P., Dronca, R., Zarour, H., Ge, Y., Lindia, J.A., Giannotti, M., Ebbinghaus, S., Kang, S.P., Hamid, O.

Volltext

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure von Cust, A.E., Drummond, M., Bishop, D.T., Azizi, L., Schmid, H., Jenkins, M.A., Hopper, J.L., Armstrong, B.K., Aitken, J.F., Kefford, R.F., Giles, G.G., Demenais, F., Goldstein, A.M., Barrett, J.H., Kanetsky, P.A., Elder, D.E., Mann, G.J., Newton‐Bishop, J.A.

Volltext

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES von Robert, C., Joshua, A.M., Weber, J.S., Ribas, A., Hodi, F.S., Kefford, R.F., Daud, A., Wolchok, J.D., Hwu, W-J., Gangadhar, T.C., Patnaik, A., Hersey, P., Dronca, R., Zarour, H., Ge, Y., Lindia, J.A., Giannotti, M., Ebbinghaus, S., Kang, S.P., Hamid, O.

Volltext

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma: Cutaneous manifestations of dabrafenib (GSK2118436) von Anforth, R.M., Blumetti, T.C.M.P., Kefford, R.F., Sharma, R., Scolyer, R.A., Kossard, S., Long, G.V., Fernandez-Peñas, P.

Volltext

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial von Menzies, A.M., Ashworth, M.T., Swann, S., Kefford, R.F., Flaherty, K., Weber, J., Infante, J.R., Kim, K.B., Gonzalez, R., Hamid, O., Schuchter, L., Cebon, J., Sosman, J.A., Little, S., Sun, P., Aktan, G., Ouellet, D., Jin, F., Long, G.V., Daud, A.

Volltext

Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Me... von Long, G.V., Sosman, J.A., Daud, A.I., Weber, J.S., Flaherty, K.T., Infante, J.R., Hamid, O., Schuchter, L., Cebon, J.S., Puzanov, I., Algazi, A.P., Kudchakar, R., Lewis, K., Hwu, W., Kefford, R.F., Sun, P., Little, S.M., Gonzalez, R., Patel, K., Kim, K.B.

Volltext

RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers von Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, H.T., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R.F.

Volltext

Stimulation of HLA‐A,B,C by IFN‐alpha. The derivation of Molt 4 variants and the differential expression of HLA‐A,B,C subsets von Burrone, O.R., Kefford, R.F., Gilmore, D., Milstein, C.

Volltext

Impaired inhibition of NF-κB activity by melanoma-associated p16INK4a mutations von Becker, T.M., Rizos, H., de la Pena, A., Leclercq, I.A., Woodruff, S., Kefford, R.F., Mann, G.J.

Volltext

Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer von Leary, J.A., Doris, C.P., Boltz, E.M., Houghton, C.R.S., Kefford, R.F., Friedlander, M.L.

Volltext

Loss of Alleles from the Distal Short Arm of Chromosome 1 Occurs Late in Melanoma Tumor Progression von Dracopoli, Nicholas C., Harnett, Paul, Bale, Sherri J., Stanger, Ben Z., Tucker, Margaret A., Housman, David E., Kefford, Richard F.

Volltext

Confirmation of chromosome 9p linkage familial melanoma von NANCARROW, D. J, MANN, G. J, FOUNTAIN, J. W, KEFFORD, R. F, HAYWARD, N. K, HOLLAND, E. A, WALKER, G. J, BEATON, S. C, WALTERS, M. K, LUXFORD, C, PALMER, J. M, DONALD, J. A, WEBER, J. L

Volltext